Bank Of America Corp Oric Pharmaceuticals, Inc. Transaction History

Bank Of America Corp

$1.06 Trillion
Q1 2024

A detailed history of Bank Of America Corp transactions in Oric Pharmaceuticals, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 201,122 shares of ORIC stock, worth $1.51 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

201,122

Previous 105,690 90.29%

Holding current value

$1.51 Million

Previous $972,000 184.47%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$8.04 - $16.03 $767,273 - $1.53 Million	95,432 Added 90.29%	201,122 $2.77 Million
Q4 2023 Feb 14, 2024	SELL	$5.41 - $9.43 $215,648 - $375,889	-39,861 Reduced 27.39%	105,690 $972,000
Q2 2023 Aug 14, 2023	BUY	$4.95 - $8.4 $100,554 - $170,637	20,314 Added 16.22%	145,551 $1.13 Million
Q1 2023 May 12, 2023	BUY	$4.26 - $6.75 $393,866 - $624,084	92,457 Added 282.05%	125,237 $713,000
Q4 2022 Feb 10, 2023	BUY	$2.41 - $5.89 $7,861 - $19,213	3,262 Added 11.05%	32,780 $193,000

Q3 2022 Nov 14, 2022	BUY	$3.28 - $5.24 $15,288 - $24,423	4,661 Added 18.75%	29,518 $95,000
Q2 2022 Aug 12, 2022	SELL	$2.7 - $7.07 $14,806 - $38,771	-5,484 Reduced 18.07%	24,857 $111,000
Q1 2022 May 16, 2022	SELL	$4.54 - $16.1 $215,749 - $765,104	-47,522 Reduced 61.03%	30,341 $162,000
Q4 2021 Feb 08, 2022	BUY	$12.01 - $20.3 $779,316 - $1.32 Million	64,889 Added 500.15%	77,863 $1.15 Million
Q3 2021 Nov 15, 2021	SELL	$15.9 - $25.22 $108,756 - $172,504	-6,840 Reduced 34.52%	12,974 $271,000
Q2 2021 Sep 13, 2021	BUY	$17.37 - $25.34 $344,169 - $502,086	19,814 New	19,814 $351,000

Others Institutions Holding ORIC

# of Institutions

113

Shares Held

59.3M

Call Options Held

302K

Put Options Held

7.7K

View Full List

About Oric Pharmaceuticals, Inc.

Ticker ORIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,576,700
Market Cap $298M
Description
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment r...

More about ORIC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.

Account

Bank Of America Corp Oric Pharmaceuticals, Inc. Transaction History